Lilly’s Cyramza Misses Primary Goal in Liver Cancer Study

June 11, 2014 1:00 PM

13 0

Eli Lilly & Co. said its Cyramza cancer drug failed to meet primary goals in a Phase III study of the drug as a secondary treatment for patients with liver cancer.

The drug maker said overall survival data favored patients who received Cyramza, also known as ramucirumab, over a placebo. However, the difference wasn’t statistically significant.

Also read: New Drug Combinations Improve Survival in Lung Cancer

Read more

To category page